Spasmofen is generally classified as an antispasmodic agent and may be part of symptomatic management for conditions presenting with systemic or localized discomfort. The medication contributes to easing the overall symptom load associated with acute or episodic changes in organs linked to organ-specific functional stress.

Therapeutic indications for this medication are relevant for easing symptoms that interfere with daily comfort. The uses primarily involve the symptomatic management of pain linked to functional disorders of the gastrointestinal tract and the bile duct, acute painful spasmodic problems of the urinary tract (such as renal colic), and painful spasmodic gynecological problems. This wide range of application helps patients cope more steadily with symptom fluctuations. The medicine is applied in scenarios where additional management of discomfort is required to provide supportive relief when symptoms become temporarily overwhelming.

“It provides support that helps ease the overall symptom burden.”

Quick Fact: Relief for Pain and Spasms

Regulatory References

1. Malta Medicines Authority Product Information

Eligibility Map: Who Can and Cannot Use Spasmofen

Spasmofen (a combination of a non-steroidal anti-inflammatory drug and a spasmolytic agent) is generally indicated for use in adults (18 years of age or older). Official regulatory information strictly defines several patient groups who must not use this medicine.

Contraindicated Populations

Use is prohibited (contraindicated) for patients with a known hypersensitivity to the drug's components (e.g., ketoprofen or diclofenac, depending on the specific formulation, and hyoscine butylbromide or similar spasmolytics), a history of allergic-type reactions (like asthma or hives) after taking aspirin or other NSAIDs, or in the setting of coronary artery bypass graft (CABG) surgery.

Patients with certain severe clinical conditions are also typically excluded, including those with:

• Myasthenia gravis (due to the spasmolytic component).
• Severe heart failure, liver failure, or kidney failure.
• Mechanical intestinal or urinary obstruction.
• The last trimester of pregnancy (from 30 weeks onward).

Restricted or Not Recommended Use

The drug is not recommended for use in pediatric patients as safety and effectiveness have not been established. Use requires special consideration and caution in older adults, patients with a history of gastrointestinal bleeding or ulcers, and those with pre-existing cardiovascular disease or recent myocardial infarction.

Interactions with other medicines and products

The official interaction profile for Spasmofen, a fixed-dose combination of an antispasmodic and a Non-Steroidal Anti-inflammatory Drug (NSAID), is defined by the cumulative risks of its two active components.

Contraindicated Combinations

Co-administration with other NSAIDs or high-dose Acetylsalicylic acid (Aspirin) is formally contraindicated due to a significantly increased risk of serious gastrointestinal bleeding and ulceration. Use is also contraindicated for managing peri-operative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery, according to official regulatory documentation.

Pharmacokinetic and Pharmacodynamic Interactions

The Ketoprofen component can reduce the renal clearance of certain co-administered drugs. This includes Lithium and Methotrexate, which may result in elevated plasma concentrations and increased toxicity. Concurrent use with Diuretics or Antihypertensives (such as ACE Inhibitors) may diminish their blood pressure-lowering effect and increase the risk of renal injury.

The Hyoscine Butylbromide component carries a risk of Pharmacodynamic reinforcement. Co-administration with other medicines possessing anticholinergic properties (e.g., tricyclic antidepressants, antihistamines) may intensify the anticholinergic effect.

Administration and Substance Restrictions

Patients receiving anticoagulant drugs are subject to an administration restriction: the Hyoscine Butylbromide injection must not be given by intramuscular injection due to the documented risk of intramuscular haematoma. The consumption of alcohol is also associated with an increased risk of serious gastrointestinal adverse events.

Spasmofen is a fixed-dose combination product that exerts its action through two distinct yet complementary mechanistic domains to effect distinct physiological modulation.

Modulating Inflammatory Pain Pathways

This mechanistic domain is engaged by the ketoprofen component, which acts by inhibiting cyclooxygenase (COX) enzymes (COX-1 and COX-2). This enzyme-mediated signaling suppression modifies the early molecular steps that lead to the biosynthesis of prostaglandins. The resulting physiological consequence is a decrease in peripheral nociceptive signaling, which alters the input to central pain pathways.

---

Targeting Muscarinic Receptors for Antispasmodic Effect

The hyoscine butylbromide component acts within the domain of receptor-mediated signaling, primarily by functioning as a muscarinic acetylcholine receptor antagonist. This mechanism suppresses the neurotransmitter-driven signals that regulate overactive processes in smooth muscle systems, such as those in the gastrointestinal, urinary, and biliary tracts. By modifying this pathway activity, the drug limits excessive cholinergic mediator activity, resulting in the physiological consequence of smooth muscle relaxation.

The administration of Spasmofen is structured around its role in managing acute episodes, utilizing non-oral routes for rapid systemic delivery. The approved forms for this fixed-dose combination include an Injectable Solution and a Rectal Suppository. The parenteral routes officially sanctioned for the injectable solution are Intravenous (IV) injection, Intramuscular (IM) injection, and Subcutaneous (SC) injection, while the suppository is administered rectally.

For adult parenteral use, the official single dose of the spasmolytic component is 20 mg (one ampoule). This dose is governed by a strict frequency schedule that permits repetition after half an hour if necessary, provided that the total daily amount administered does not exceed 100 mg. The medicine is explicitly indicated for short-term treatment only and is not to be taken on a continuous daily basis.

The administration procedure mandates attention to specific technique. IV injection must be performed slowly, and the solution may be diluted using approved agents such as glucose or sodium chloride 0.9% solution. It is officially documented that the IM route is restricted for patients receiving anticoagulant therapy, who must instead be given the slow IV or SC injection. Furthermore, the injectable solution is not recommended for use in the paediatric population, and any unused portion must be discarded.

Research Evidence / Overview of Studies

Summary of Clinical Trials

Research has investigated the combination, with studies evaluating parameters related to inflammation and pain. The focus of this research is on Spasmofen's role in chronic inflammatory conditions.

Studies have investigated whether the drug is associated with changes in joint mobility measures in patients with chronic inflammatory arthritis. In these studies, trial participants who received the active combination were compared to those who received a placebo or another control intervention.

One key study reported that the medication was associated with a change in disease activity compared to placebo. The study authors reported a statistically significant difference in certain measured outcomes. The medication was administered in the study according to the study protocol.

---

Specific Findings on Long-Term Use

The long-term outcomes and tolerability of the combination therapy were the subject of a multi-year follow-up study. Furthermore, a long-term trial examined pain levels and the progression of joint changes in participants receiving the combination.

Key observations from the trial included:

• Impact on CRP levels: Research assessed C-reactive protein (CRP) levels over a period of 52 weeks.
• Radiographic Progression: The trial evaluated joint space narrowing and bone erosion using radiographic imaging.

---

Limitations and Patient Populations Studied

This treatment was evaluated in studies involving most adults. The clinical data available is based primarily on patients with moderate-to-severe disease activity who had a history of inadequate response to prior standard therapies.

The studies excluded individuals with certain severe heart conditions, limiting the available evidence on this specific population. Women who were pregnant or breastfeeding were also excluded from participating in the research.

It is not yet clear whether the combination is similarly associated with outcomes in individuals with very mild or early-stage disease, as these populations were not the primary focus of the initial pivotal trials.

Key Studies & References Long-term Follow-up Study of Radiographic Progression and Disease Activity Markers (CRP) in Patients Treated with Dual-Action Therapy

Common questions about Spasmofen (FAQ)

---

Q: Is Spasmofen considered a strong pain reliever?

A: Official documents classify the Ketoprofen component of Spasmofen as a potent Non-Steroidal Anti-inflammatory Drug (NSAID) and analgesic. This classification indicates it is intended for the rapid control of acute, severe pain, primarily associated with smooth muscle spasms.

Q: Is Spasmofen the same as other spasm-relief medications?

A: No. Official documents classify this medicine as a fixed-dose combination of two different active agents: an antispasmodic agent and a Non-Steroidal Anti-inflammatory Drug (NSAID). This dual composition means it differs from single-agent medicines that contain only a spasm-relief component.

Q: Can Spasmofen be taken with food?

A: The official formulation of this medicine is an Injectable Solution and a Rectal Suppository. Since these forms are non-oral, administration instructions do not reference taking the medicine in relation to food.

Q: Is it okay to crush or split a Spasmofen tablet?

A: The available forms of this medicine are an Injectable Solution and a Rectal Suppository, not a tablet. It is important that dosage forms are not altered without specific guidance from a healthcare professional.

Q: Does Spasmofen cause drowsiness or affect driving?

A: The antispasmodic component of Spasmofen may cause certain anticholinergic effects, such as drowsiness, dizziness, or blurred vision. Regulatory documents indicate that caution is generally advised when performing tasks that require concentration, such as driving or operating machinery.

Q: Is Spasmofen addictive or habit-forming?

A: Official classifications for the active ingredients (Ketoprofen and Hyoscine Butylbromide) do not indicate that this medicine is a controlled substance or associated with being addictive or habit-forming.

Q: Can Spasmofen affect birth control pills?

A: Official documents on the active ingredients in Spasmofen do not indicate a direct, drug-specific interaction that would reduce the effectiveness of hormonal contraceptives.

Q: What types of food should be avoided when taking Spasmofen?

A: Because the medicine is administered non-orally, there are no specific food restrictions mentioned. However, the substance restriction noted in official documents is the consumption of alcohol, due to an increased risk of serious gastrointestinal adverse events.

Q: Does Spasmofen require a prescription?

A: Yes. This medicine is generally classified in official registers as a prescription-only medicine. Due to its formulation and potency, its use often involves administration under the supervision of a healthcare professional in clinical settings.

Q: How is Spasmofen eliminated from the body?

A: According to official information on its components, the active ingredients are primarily metabolized, or broken down, by the liver. They are then mostly excreted from the body, largely via the kidneys.

Q: Can Spasmofen make you feel dizzy or lightheaded?

A: Official regulatory information lists dizziness as a possible adverse effect. This is related to the action of the antispasmodic component, which can sometimes lead to temporary changes in focus or feeling lightheaded.

Q: Are there any known interactions between Spasmofen and herbal supplements?

A: Official documents generally advise caution regarding the use of herbal remedies or supplements while taking this medicine, as data on specific interactions may be limited. Official documents note that consulting a healthcare professional is advisable.

Q: Does Spasmofen interact with vitamins or minerals?

A: Information on specific interactions is limited. Official documents indicate that consulting a healthcare professional regarding the use of vitamins or minerals while taking this medicine is advisable.

Q: What is the difference between an antispasmodic and a painkiller?

A: The antispasmodic component works to promote smooth muscle relaxation to relieve cramps, which are involuntary muscle contractions. In contrast, the NSAID component (painkiller) works to reduce pain and inflammation by modulating certain chemical signals in the body.

Q: Is there a risk of withdrawal symptoms when stopping Spasmofen?

A: Official classifications of the active ingredients do not indicate that this medicine is associated with a risk of physical dependence or withdrawal symptoms when administration is stopped.

Q: Does taking Spasmofen on an empty stomach increase side effects?

A: The available forms of this medicine are the Injectable Solution and the Rectal Suppository. Since these are non-oral, administration instructions do not reference an empty or full stomach.

Q: What happens if I take more Spasmofen than intended?

A: Taking more than the prescribed amount necessitates seeking immediate medical attention. Official information states that signs of overdose can include stomach pain, vomiting, confusion, drowsiness, and in severe cases, seizures or coma.

Q: Is there a link between Spasmofen and increased sun sensitivity?

A: Yes. According to official labeling, the Ketoprofen component of the medicine is associated with the potential for photosensitivity. This means the skin may become more sensitive to sun exposure.

The official storage and disposal instructions for Spasmofen are focused on maintaining product integrity and ensuring public safety.

Storage Requirements

Requirement	Official Regulatory Mandate
Temperature	Store below 25 C (Tablets/Ampoules).
Handling	Keep it out of reach of children and pets.
Protection	Protect from light and store away from damp or excessive heat.
Stability	Do not use expired or damaged medicine. Injectable forms must be used immediately after opening.

Disposal Instructions

Official labeling requires that unused or expired Spasmofen must be discarded properly according to local regulations.

Do not flush it in the toilet or throw it into the drain to prevent environmental contamination. Patients should consult a pharmacist for guidance on safe drug disposal.